Why is "PCSK9" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-05-09 18:24:58
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
PCSK9 entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-05-09 and was most recently seen on 2026-05-09.
Wikipedia Overview
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes (orthologs) are found across many species. As with many proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. The PCSK9 gene also contains one of 27 loci associated with increased risk of coronary artery disease.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Once-Monthly, Self-Administered PCSK9 Inhibitor Lerochol Now Available - Medical Professionals Reference
-
Base editing and silencing of PCSK9 shows clinical promise in humans - Nature
-
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide - The New England Journal of Medicine
-
Q&A: Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 65% in Phase 3 Trial, With Ann Marie Navar, MD, PhD - Patient Care Online
-
Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering - TCTMD.com
-
Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks - AJMC
-
Merck Advances Scalable Manufacturing for Oral PCSK9 Therapy - BioPharm International
-
New treatment cuts bad cholesterol by nearly 50% without statins - ScienceDaily
-
First Oral PCSK9 Inhibitor Rivals Injectables - Medscape
-
MSD boasts data for oral PCSK9 inhibitor as add on therapy - Clinical Trials Arena
-
Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals - Fierce Biotech
-
PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke - www.heart.org
-
Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers - Pharmaceutical Executive
-
FDA Approves Once-Monthly PCSK9 Injection for LDL-C Reduction - AJMC
-
PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV - TCTMD.com
-
Association between PCSK9 inhibitor use and risk of age-related macular degeneration - Nature
-
FDA approves Lerochol as monthly PCSK9 inhibitor for hypercholesterolemia - Clinical Trials Arena
-
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol - AJMC
-
PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies - Nature
-
Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy - Nature
-
Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort - Nature
-
Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids - TCTMD.com
-
Oral PCSK9 inhibitor lowers LDL by up to 60% - Healio
-
ACC26: Merck & Co.'s oral PCSK9 yields over 64% LDL-C drop in add-on setting - FirstWord Pharma
-
Experimental pill dramatically reduces ‘bad’ cholesterol: Newsroom - UT Southwestern Medical Center
-
Lerodalcibep: Monthly PCSK9 Inhibitor to Lower LDL - Pharmacy Times
-
Merck’s Oral PCSK9 Advances And Gardasil Trial Reframe Growth Story - Yahoo Finance
-
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma | Scientific Reports - Nature
-
Systemic PCSK9 elevation characterises autoimmune liver disease across sexes - Nature
-
Q&A: How Oral PCSK9 Inhibitors Will Revolutionize Pharmacists' Role in Cholesterol Control - Pharmacy Times
-
Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol - Fierce Pharma
-
CORALreef AddOn: Novel PCSK9 Inhibitor Reduces LDL-C in Patients Not Meeting Goals - American College of Cardiology
-
What Are PCSK9 Inhibitors Used For? - Healthline
-
MSD’s oral PCSK9 scores Phase III hat-trick - Clinical Trials Arena
-
Depression Risk With PCSK9 Inhibitors Versus Statins in Hyperlipidemia - medRxiv
-
Cholesterol-modulating effects of Korean red ginseng (KRG) targeting PCSK9 in hyperlipidemia | Scientific Reports - Nature
-
Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots - BioPharma Dive
-
Third-Generation PCSK9 Inhibitor Approved for High Cholesterol - MedPage Today
-
Merck’s Oral PCSK9 Inhibitor Demonstrates Efficacy in Hypercholesterolemia - Applied Clinical Trials Online
-
Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins - Nature
-
Shifting PCSK9 inhibition ‘upstream’ for high-risk primary prevention - Healio
-
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 - Yahoo Finance
-
Oral PCSK9 Inhibition and the CORALreef AddOn Trial - Pharmacy Times
-
Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts - Fierce Biotech
-
Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease - Frontiers
-
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction - PR Newswire
-
PCSK9 inhibitor lowers risk of first heart attack and stroke in high-risk adults - Medical Xpress
-
Physician Views Preview: Could Merck & Co.'s oral PCSK9 inhibitor redefine LDL-C lowering in HeFH? - FirstWord Pharma
-
Expert: Debunking Cholesterol Myths and the Rise of Oral PCSK9 Inhibitors - Pharmacy Times
-
Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis - American Heart Association Journals
-
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial - Nature
-
Journal of Digestive Diseases | JSH Journal - Wiley Online Library
-
Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions - TCTMD.com
-
Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication: - JACC Journals
-
New Pill From Merck Could Slash Cholesterol Levels, Trials Show - The New York Times
-
Automating the Clinical Interpretation of LDLR, APOB, and PCSK9 Variants: A Web-Based Platform for FH Diagnosis - medRxiv
-
The high cost of PCSK9 inhibitors like Repatha - KevinMD.com
-
PCSK9 Inhibitor Found Effective for Primary Prevention - Medscape
-
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke - The New England Journal of Medicine
-
Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates - Nature
-
PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study - Nature
-
PCSK9’s second act: From antibodies to gene editing - Labiotech.eu
-
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis - MedPage Today
-
Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C by 64.6% in Phase 3 Trial vs Nonstatin Therapies - Patient Care Online
-
PCSK9 Promotes Atherosclerotic Plaque Instability by Inducing VSMC Ferroptosis through the YAP1–NUPR1 Axis - Science Partner Journals
-
Inclisiran Reduces LDL-C in Patients Intolerant to Statins, PCSK9 Inhibitors - Pharmacy Times
-
PCSK9 Inhibitor Market | Global Market Analysis Report - 2035 - Future Market Insights
-
Merck dives into regulatory talks after oral PCSK9 delivers 3rd phase 3 win - Fierce Biotech
-
Expanding the Role of PCSK9 Inhibitors in ASCVD Treatment - HCPLive
-
MSD’s Oral PCSK9 Inhibitor For Hypercholesterolemia Among Seven New EU Filings - Citeline News & Insights
-
PCSK9 inhibitors for abdominal aortic aneurysm - Penn Medicine
-
Merck & Co.'s oral PCSK9 contender clears third late-stage hurdle - FirstWord Pharma
-
Trends in Utilization, Cost-Effectiveness, and Budget Impact of PCSK9 Inhibitors - Leerink Partners
-
First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease - MedPage Today
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - Business Wire
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins - Yahoo Finance
-
Dr. Roach: Providing more information about Repatha for cholesterol - The Detroit News
-
PCSK9 Inhibitors Are Found Safe, Effective in Solid Organ Transplant Recipients - Pharmacy Times
-
PCSK9 inhibitors prove effective for ‘ultrahigh-risk’ cardiovascular patients: expert - koreabiomed.com
-
PCSK9 inhibitor combined with a statin may help reduce LDL cholesterol after heart transplant - News-Medical
-
Sanofi/Regeneron & Amgen Settle Dispute Over PCSK9 Inhibitors, Praluent® & Repatha® - Pearce IP
-
PCSK9 inhibitors disclosed in Avioris Bio patent - BioWorld News
-
PCSK9 approval marks shift to long-acting LDL-C control in high-risk cardio patients - The Pharma Letter
-
KOL Views Preview: How will the latest data on Repatha and enlicitide decanoate reshape the anti-PCSK9 landscape? - FirstWord Pharma
-
Experimental Pill Cuts LDL Cholesterol by Up to 60% - Technology Networks
-
Merck (MRK) Is Up 8.5% After Promising Oral PCSK9 Cholesterol Drug Trial Results – Has The Bull Case Changed? - Yahoo Finance
-
Men Experience Greater LDL Reductions Than Women Across Multiple Lipid-Lowering Medications, with the Largest Gap for PCSK9 Inhibitors - Epic Research
-
AHA25: Merck & Co.'s oral PCSK9 more than halves LDL cholesterol in key studies - FirstWord Pharma
-
AHA: MSD's oral PCSK9 matches injectables - pharmaphorum
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins - BioSpace
-
LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report - American Heart Association Journals
-
PCSK9 Emerges as Early Marker of Autoimmune Liver Disease - EMJ
-
New Cholesterol-Lowering Strategy Silences PCSK9, Avoiding Statin Side Effects - Inside Precision Medicine
-
Accurate and rapid single nucleotide variation detection in PCSK9 gene using nanopore sequencing - Frontiers
-
Merck to present trial data on oral PCSK9 inhibitor at ACC.26 - Investing.com
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial - Business Wire
-
LIB takes aim at cholesterol market with new PCSK9 option - pharmaphorum
-
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins - Seeking Alpha
-
PCSK9 Inhibitor After Heart Transplant Turns in Mixed Results - MedPage Today
-
The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.